Non-Hodgkin's B cell lymphoma (AIDS-lymphoma)is seen in greatly-evaluated frequency in AIDS and HIV infection. In this proposal, studies to delineate immune system changes in HIV infection, relevant to the development of AIDS-lymphoma, are presented. While the dominant immune system change seen in AIDS is a severe functional and numerical loss of CD4 T cells, various other immune system changes are seen, including a marked increase in polyclonal B cell activation. The high frequency of B cell lymphoma seen in HIV infection may result, in part, from this chronic polyclonal B cell stimulation. Also, loss of immunoregulatory control of y-herpesvirus (EBV, HHV8) infected/activated B cells may contribute to AIDS-lymphoma. HHV8 encodes a viral IL6 homologue (vIL6). Studies described in this proposal will examine how vIL6 interacts with human B cells, in terms of receptor utilization, signal transduction, and biological effects. In other preliminary studies, key IL6 receptor element, IL6-Rx'CD126' was seen to be over- expressed in HIV infection, and to be involved in aberrant signaling (huIL6). Studies to define factors that could enhance IL6Rx expression, or modulate IL6Rx-mediated signaling, are proposed. Finally, preliminary studies indicate that people with advanced HIV disease show marked phenotypic changes in circulating B cells and CD8 T cells, including the over-expression of B/T cell surface stimulatory molecules. Studies to examine mechanisms that may be involved in the up-regulation of these molecules are proposed.
The specific aims are to: 1) define the biological effects of vIL6, and the receptor elements and signaling pathways utilized by this viral cytokine, on human B lymphocytes, 2) elucidate factors that contribute to IL6Rx over-expression on B cells and monocytes, and modulate IL6 receptor-mediated signaling, in HIV infection, and 3) characterize changes in immune cell subpopulations associated with enhanced B cell hyper-stimulation, or with the development of lymphoma, which are seen in people with advanced HIV disease. The accomplishment of these specific aims will provide information on HIV-induced immune dysfunction and the development of AIDS-lymphoma, may suggest new avenues for treatment, and could lead to screening technologies for the early detection of lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057152-08
Application #
2894944
Study Section
Special Emphasis Panel (ZRG5-ARRC (02))
Program Officer
Finerty, John F
Project Start
1992-04-03
Project End
2002-04-30
Budget Start
1999-05-01
Budget End
2000-04-30
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Bonavida, Benjamin (2014) RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-?B/Snail/YY1/RKIP resistance-driver loop. Crit Rev Oncog 19:431-45
Thapa, Dharma R; Hussain, Shehnaz K; Tran, Wen-Ching et al. (2014) Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J Acquir Immune Defic Syndr 66:229-37
Vendrame, Elena; Hussain, Shehnaz K; Breen, Elizabeth Crabb et al. (2014) Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 23:343-9
Widney, Daniel P; Olafsen, Tove; Wu, Anna M et al. (2013) Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7. PLoS One 8:e72414
Daniels-Wells, Tracy R; Helguera, Gustavo; Rodríguez, José A et al. (2013) Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol In Vitro 27:220-31
Hussain, Shehnaz K; Zhu, Weiming; Chang, Shen-Chih et al. (2013) Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 22:295-307
Daniels, Tracy R; Bernabeu, Ezequiel; Rodríguez, José A et al. (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820:291-317
Daniels, Tracy R; Martínez-Maza, Otoniel; Penichet, Manuel L (2012) Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother 61:1535-46
Thapa, Dharma R; Bhatia, Kishor; Bream, Jay H et al. (2012) B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas. AIDS 26:1177-80
Daniels, Tracy R; Leuchter, Richard K; Quintero, Rafaela et al. (2012) Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother 61:991-1003

Showing the most recent 10 out of 49 publications